Literature DB >> 27502446

Sultiame revisited: treatment of refractory absence seizures.

Kathleen M Gorman1, Amre Shahwan1.   

Abstract

Sultiame is recommended for the treatment of benign epilepsy of childhood with centrotemporal spikes, electrical status epilepticus during slow-wave sleep, as well as other genetic (idiopathic) focal epilepsies. Sultiame is not traditionally considered a treatment choice for idiopathic generalised epilepsy, and it does not appear on the list of drugs recommended for treatment of absence seizures. We report the efficacy of sultiame in treating three children with drug-resistant absence seizures and discuss the potential use of sultiame beyond the idiopathic focal epilepsies.

Entities:  

Keywords:  absence seizure; childhood absence epilepsy; idiopathic focal epilepsy; refractory; sulthiame

Mesh:

Substances:

Year:  2016        PMID: 27502446     DOI: 10.1684/epd.2016.0850

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  2 in total

Review 1.  Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents.

Authors:  Giulia Iapadre; Ganna Balagura; Luca Zagaroli; Pasquale Striano; Alberto Verrotti
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

2.  Amantadine for the Treatment of Refractory Absence Seizures in Children.

Authors:  Mini Sreedharan; Kalpana Devadathan; Habib K Pathan; Shiji Chalipat; Kunju P A Mohammed
Journal:  J Pediatr Neurosci       Date:  2018 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.